High dose-intense chemotherapy alone or in combination with interleukin-2 for small cell lung cancer: A pilot study

Camillo Francesco Pollera, Federico Calabresi, Monica Moreschi, Enzo Maria Ruggeri, Diana Giannarelli, Rosalba Masciulli, Ugo Testa, Cesare Peschle

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Given the antitumor activity of interleukin-2 (IL-2) against some drug-resistant cancer cells, 17 previously untreated patients with small cell lung cancer entered a pilot study to evaluate the feasibility, efficacy, and immunological effects of combining 12-week high dose-intense chemotherapy based on a modified Evans regimen (CAV/PE) with different IL-2 schedules (6-12 MU/m2 week as a 48-72-h infusion using the same cumulative dose, 72 MU/m2). Despite significant myelotoxicity, up to 70% of the intended dose intensity was delivered, showing no differences with regard to the IL-2 schedule used. Immunotherapy-induced toxicity was usually mild and manageable. No limiting effects were observed in patients receiving immunotherapy except for a very poor compliance to the 12-week IL-2 regimen. The low-dose 72-h infusion was the optimal IL-2 schedule. As given in this study, neither of the alternating CAV/PE regimens abrogated the effects of IL-2 on T-cell and NK-cell subsets, showing typical kinetics with rebound in lymphocytes following each discontinuation of the IL-2. While immunological changes cannot predict the antitumor effect of IL-2, they are consistent with those described for IL-2 alone, suggesting its compatibility with high dose-intense chemotherapy. Although no definite advantages have been demonstrated in this small pilot study with significant unbalanced prognostic factors (12% 2-year survival), both the preserved immunostimulatory effects and the lack of limiting overlapping toxicity make this combined approach promising and worthy of further clinical investigation.

Original languageEnglish
Pages (from-to)574-587
Number of pages14
JournalCancer Investigation
Volume12
Issue number6
DOIs
Publication statusPublished - 1994

Fingerprint

Small Cell Lung Carcinoma
Interleukin-2
Drug Therapy
Appointments and Schedules
Immunotherapy
Natural Killer Cells
Lymphocytes
T-Lymphocytes
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

High dose-intense chemotherapy alone or in combination with interleukin-2 for small cell lung cancer : A pilot study. / Pollera, Camillo Francesco; Calabresi, Federico; Moreschi, Monica; Ruggeri, Enzo Maria; Giannarelli, Diana; Masciulli, Rosalba; Testa, Ugo; Peschle, Cesare.

In: Cancer Investigation, Vol. 12, No. 6, 1994, p. 574-587.

Research output: Contribution to journalArticle

Pollera, CF, Calabresi, F, Moreschi, M, Ruggeri, EM, Giannarelli, D, Masciulli, R, Testa, U & Peschle, C 1994, 'High dose-intense chemotherapy alone or in combination with interleukin-2 for small cell lung cancer: A pilot study', Cancer Investigation, vol. 12, no. 6, pp. 574-587. https://doi.org/10.3109/07357909409023042
Pollera, Camillo Francesco ; Calabresi, Federico ; Moreschi, Monica ; Ruggeri, Enzo Maria ; Giannarelli, Diana ; Masciulli, Rosalba ; Testa, Ugo ; Peschle, Cesare. / High dose-intense chemotherapy alone or in combination with interleukin-2 for small cell lung cancer : A pilot study. In: Cancer Investigation. 1994 ; Vol. 12, No. 6. pp. 574-587.
@article{ad3e3fc0219447358643cb1e9a3a7fad,
title = "High dose-intense chemotherapy alone or in combination with interleukin-2 for small cell lung cancer: A pilot study",
abstract = "Given the antitumor activity of interleukin-2 (IL-2) against some drug-resistant cancer cells, 17 previously untreated patients with small cell lung cancer entered a pilot study to evaluate the feasibility, efficacy, and immunological effects of combining 12-week high dose-intense chemotherapy based on a modified Evans regimen (CAV/PE) with different IL-2 schedules (6-12 MU/m2 week as a 48-72-h infusion using the same cumulative dose, 72 MU/m2). Despite significant myelotoxicity, up to 70{\%} of the intended dose intensity was delivered, showing no differences with regard to the IL-2 schedule used. Immunotherapy-induced toxicity was usually mild and manageable. No limiting effects were observed in patients receiving immunotherapy except for a very poor compliance to the 12-week IL-2 regimen. The low-dose 72-h infusion was the optimal IL-2 schedule. As given in this study, neither of the alternating CAV/PE regimens abrogated the effects of IL-2 on T-cell and NK-cell subsets, showing typical kinetics with rebound in lymphocytes following each discontinuation of the IL-2. While immunological changes cannot predict the antitumor effect of IL-2, they are consistent with those described for IL-2 alone, suggesting its compatibility with high dose-intense chemotherapy. Although no definite advantages have been demonstrated in this small pilot study with significant unbalanced prognostic factors (12{\%} 2-year survival), both the preserved immunostimulatory effects and the lack of limiting overlapping toxicity make this combined approach promising and worthy of further clinical investigation.",
author = "Pollera, {Camillo Francesco} and Federico Calabresi and Monica Moreschi and Ruggeri, {Enzo Maria} and Diana Giannarelli and Rosalba Masciulli and Ugo Testa and Cesare Peschle",
year = "1994",
doi = "10.3109/07357909409023042",
language = "English",
volume = "12",
pages = "574--587",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - High dose-intense chemotherapy alone or in combination with interleukin-2 for small cell lung cancer

T2 - A pilot study

AU - Pollera, Camillo Francesco

AU - Calabresi, Federico

AU - Moreschi, Monica

AU - Ruggeri, Enzo Maria

AU - Giannarelli, Diana

AU - Masciulli, Rosalba

AU - Testa, Ugo

AU - Peschle, Cesare

PY - 1994

Y1 - 1994

N2 - Given the antitumor activity of interleukin-2 (IL-2) against some drug-resistant cancer cells, 17 previously untreated patients with small cell lung cancer entered a pilot study to evaluate the feasibility, efficacy, and immunological effects of combining 12-week high dose-intense chemotherapy based on a modified Evans regimen (CAV/PE) with different IL-2 schedules (6-12 MU/m2 week as a 48-72-h infusion using the same cumulative dose, 72 MU/m2). Despite significant myelotoxicity, up to 70% of the intended dose intensity was delivered, showing no differences with regard to the IL-2 schedule used. Immunotherapy-induced toxicity was usually mild and manageable. No limiting effects were observed in patients receiving immunotherapy except for a very poor compliance to the 12-week IL-2 regimen. The low-dose 72-h infusion was the optimal IL-2 schedule. As given in this study, neither of the alternating CAV/PE regimens abrogated the effects of IL-2 on T-cell and NK-cell subsets, showing typical kinetics with rebound in lymphocytes following each discontinuation of the IL-2. While immunological changes cannot predict the antitumor effect of IL-2, they are consistent with those described for IL-2 alone, suggesting its compatibility with high dose-intense chemotherapy. Although no definite advantages have been demonstrated in this small pilot study with significant unbalanced prognostic factors (12% 2-year survival), both the preserved immunostimulatory effects and the lack of limiting overlapping toxicity make this combined approach promising and worthy of further clinical investigation.

AB - Given the antitumor activity of interleukin-2 (IL-2) against some drug-resistant cancer cells, 17 previously untreated patients with small cell lung cancer entered a pilot study to evaluate the feasibility, efficacy, and immunological effects of combining 12-week high dose-intense chemotherapy based on a modified Evans regimen (CAV/PE) with different IL-2 schedules (6-12 MU/m2 week as a 48-72-h infusion using the same cumulative dose, 72 MU/m2). Despite significant myelotoxicity, up to 70% of the intended dose intensity was delivered, showing no differences with regard to the IL-2 schedule used. Immunotherapy-induced toxicity was usually mild and manageable. No limiting effects were observed in patients receiving immunotherapy except for a very poor compliance to the 12-week IL-2 regimen. The low-dose 72-h infusion was the optimal IL-2 schedule. As given in this study, neither of the alternating CAV/PE regimens abrogated the effects of IL-2 on T-cell and NK-cell subsets, showing typical kinetics with rebound in lymphocytes following each discontinuation of the IL-2. While immunological changes cannot predict the antitumor effect of IL-2, they are consistent with those described for IL-2 alone, suggesting its compatibility with high dose-intense chemotherapy. Although no definite advantages have been demonstrated in this small pilot study with significant unbalanced prognostic factors (12% 2-year survival), both the preserved immunostimulatory effects and the lack of limiting overlapping toxicity make this combined approach promising and worthy of further clinical investigation.

UR - http://www.scopus.com/inward/record.url?scp=0028032565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028032565&partnerID=8YFLogxK

U2 - 10.3109/07357909409023042

DO - 10.3109/07357909409023042

M3 - Article

C2 - 7994592

AN - SCOPUS:0028032565

VL - 12

SP - 574

EP - 587

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 6

ER -